Market Flux Event
Teva Drops Phase 2 Trial of Emrusolmin for Multiple System Atrophy After Futility Analysis
Read this in the Market Flux appTeva Pharmaceutical Industries is discontinuing its Phase 2 TOPAS-MSA study of emrusolmin, also known as TEV-'286, a drug candidate targeting multiple system atrophy, a rare and fatal neurodegenerative disorder. The decision follows an interim futility analysis that indicated the mid-stage trial was unlikely to meet its primary endpoints.
Shares of Teva fell approximately 3.3% in premarket trading on the news, reflecting investor disappointment over the setback to the company's neuroscience pipeline.
© AI-generated summary is provided by Market Flux
Sources
- BioStocks$TEVA to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
- Seeking AlphaTeva discontinues Phase 2 study of Emrusolmin in multiple system atrophy
- ReutersTeva to discontinue mid-stage neurodegenerative disorder study
- OpenOutcrier$DRUG (-45.8% pre) FDA places Bright Minds Biosciences BMB-101 trial on partial hold
- TheflynewsTeva to discontinue TOPAS-MSA study $TEVA